CD274 and non-small cell lung carcinoma: Taken together, these results support pembrolizumab monotherapy as a potentially reasonable treatment option for the 34% of patients with TPS scores 1-49% who are IRS-H (Fig. 4c and S8), consistent with a recent report assessing TMB across PD-L1 IHC strata in patients with first line NSCLC treated with PD-(L)1 monotherapy27, and more broadly suggests potential utility in identifying patients who may benefit from monotherapy PD-(L)1 vs. combination therapy in current indications.